Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Dig Dis Sci ; 68(2): 685-698, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36100828

RESUMO

BACKGROUND: The incidence of extrahepatic malignancies (EHMs) after hepatitis C virus (HCV) eradication by interferon (IFN)-based and IFN-free direct-acting antivirals (DAAs) treatment remains unclear. AIMS: The aim was to evaluate the cumulative incidence of EHMs diagnosed for the first time after the antiviral treatments. METHODS: We analyzed a total 527 patients with chronic HCV infection and without prior history of any malignancies who achieved sustained virological response by antiviral treatments, including IFN-based (n = 242) or IFN-free DAAs (n = 285). The baseline predictors for EHM occurrence were analyzed using Cox regression analysis. RESULTS: Thirty-two patients were diagnosed with EHMs, 14 in IFN-based and 18 in IFN-free DAAs, respectively. The total duration of follow-up was 1,796 person-years in IFN-based and 823 person-years in IFN-free DAAs. The incidence of EHMs in IFN-based and IFN-free DAAs was 7.8 and 21.9 per 1,000 person-years, respectively. The cumulative incidence of EHMs was significantly higher in IFN-free DAAs than IFN-based (p = 0.002). IFN-free DAAs was a single independent predictor for incidence of EHMs (p = 0.012). As for gender, the incidence of EHMs was significantly higher in IFN-free DAAs only in the female cohort (p = 0.002). After propensity score matching, IFN-free DAAs was a single independent predictor for incidence of EHMs in the female patients (p = 0.045). CONCLUSIONS: The incidence of EHMs after HCV eradication is higher in IFN-free DAAs than IFN-based regimens, especially in female patients. We should carefully follow-up not only HCC but also EHMs after IFN-free DAAs regimens.


Assuntos
Carcinoma Hepatocelular , Hepatite C Crônica , Hepatite C , Neoplasias Hepáticas , Humanos , Feminino , Interferons/uso terapêutico , Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Incidência , Carcinoma Hepatocelular/patologia , Neoplasias Hepáticas/patologia , Hepacivirus , Hepatite C/tratamento farmacológico
2.
Intern Med ; 62(14): 2077-2083, 2023 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-36450462

RESUMO

Asymptomatic splenic nodules were detected incidentally in two middle-aged women at an annual checkup. They showed no abnormalities on laboratory tests, but imaging studies revealed splenic nodules. No other localized lesions were found. Splenic nodules were hypoechoic on ultrasonography (US), hypovascular on contrast-enhanced computed tomography, and showed a low intensity on T2-weighted magnetic resonance imaging. We performed US-guided percutaneous aspiration biopsies using 21-gauge needles without complications, including bleeding. Pathological specimens showed noncaseating granulomas, so both patients were diagnosed with isolated splenic sarcoidosis. A US-guided fine-needle aspiration biopsy is a safe and useful method for diagnosing splenic nodules.


Assuntos
Sarcoidose , Esplenopatias , Pessoa de Meia-Idade , Humanos , Feminino , Biópsia por Agulha Fina/métodos , Sarcoidose/diagnóstico por imagem , Sarcoidose/patologia , Biópsia Guiada por Imagem , Esplenopatias/diagnóstico , Ultrassonografia , Ultrassonografia de Intervenção
3.
Intern Med ; 60(12): 1847-1853, 2021 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-33456046

RESUMO

A 72-year-old woman with advanced lung cancer had received systemic chemotherapy including atezolizumab. About three months after the initial administration of atezolizumab, her liver enzyme levels increased. The histopathological findings of the initial liver biopsy revealed acute inflammatory infiltrate, predominantly CD3+, CD4+ and CD8+ T lymphocytes, in the hepatic lobules. We diagnosed her with atezolizumab-induced immune-related acute hepatitis. Oral corticosteroid therapy successfully improved the elevation of serum aminotransferases. A sequential liver biopsy demonstrated the rapid progression of liver fibrosis. Because hepatocellular carcinoma occurs most often in advanced cases of chronic liver disease, we should pay close attention to immune-related acute hepatic injury when treating patients with advanced liver diseases using atezolizumab.


Assuntos
Anticorpos Monoclonais Humanizados , Neoplasias Hepáticas , Idoso , Anticorpos Monoclonais Humanizados/efeitos adversos , Feminino , Humanos , Cirrose Hepática/induzido quimicamente , Neoplasias Hepáticas/tratamento farmacológico
4.
Med Mol Morphol ; 54(1): 60-67, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32607777

RESUMO

Hemochromatosis is a clinical syndrome characterized by iron overload in various organs. We present here a case of type 4 hereditary hemochromatosis due to heterozygous mutation in SLC40A1 gene (p.D157A). SLC40A1 encodes ferroportin, a macromolecule only known as iron exporter from mammalian cells. He first presented symptoms correlated with hypopituitarism. Furthermore, marked hyperferritinemia and high transferrin saturation were revealed in combination with the findings of iron overload in the liver, spleen and pituitary gland by computed tomography and magnetic resonance imaging. Liver biopsy revealed iron deposition in both hepatocytes and Kupffer cells. SLC40A1 mutations are considered to cause wide heterogeneity by various ferroportin mutations. Thus, clinicopathological examinations seem to be very important for diagnosing phenotype of type 4 hemochromatosis in addition to the gene analysis. We diagnosed him as type 4B hereditary hemochromatosis (ferroportin-associated hemochromatosis) by the findings of high transferrin saturation and iron deposition in hepatocytes, and then started iron chelating treatment. We should suspect the possibility of hereditary hemochromatosis even in Japanese with severe iron overload. Although the same mutation in SLC40A1 gene (p.D157A) had been reported to cause "loss of function" phenotype, we considered that the mutation of our case caused "gain of function" phenotype.


Assuntos
Proteínas de Transporte de Cátions/deficiência , Hemocromatose/diagnóstico , Hipopituitarismo/diagnóstico , Idoso , Biópsia , Proteínas de Transporte de Cátions/sangue , Proteínas de Transporte de Cátions/genética , Análise Mutacional de DNA , Hemocromatose/sangue , Hemocromatose/complicações , Hemocromatose/genética , Heterozigoto , Humanos , Hipopituitarismo/sangue , Hipopituitarismo/genética , Fígado/diagnóstico por imagem , Fígado/patologia , Testes de Função Hepática , Imageamento por Ressonância Magnética , Masculino , Hipófise/diagnóstico por imagem , Tomografia Computadorizada por Raios X
5.
Intern Med ; 59(1): 77-81, 2020 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-31511488

RESUMO

A 37-year-old Wilson disease patient treated with D-penicillamine visited our hospital for the evaluation of his liver function. Laboratory data showed a low serum copper level and ceruloplasmin. The ratio of urinary copper to urinary creatinine in a spot urinary analysis after 4 days' cessation of D-penicillamine was under 0.1. We concluded that the copper chelation was excessive and changed D-penicillamine to zinc acetate. However, his liver function test results did not normalize. We performed a liver biopsy and discovered a high copper content. The liver dysfunction was improved after resuming chelating therapy. Accurate measurement of the hepatic copper content via a biopsy is important for the adequate management of this disease.


Assuntos
Ceruloplasmina/metabolismo , Cobre/metabolismo , Degeneração Hepatolenticular/patologia , Fígado/patologia , Adulto , Biópsia , Quelantes/uso terapêutico , Gerenciamento Clínico , Degeneração Hepatolenticular/tratamento farmacológico , Degeneração Hepatolenticular/metabolismo , Humanos , Fígado/metabolismo , Testes de Função Hepática , Masculino , Penicilamina/uso terapêutico , Acetato de Zinco/uso terapêutico
6.
Intern Med ; 59(4): 527-532, 2020 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-31611530

RESUMO

A 69-year-old man was diagnosed with a liver abscess and received antibiotics at a local hospital. He was referred to our hospital due to a persistent fever. He had hepatic masses protruding from the liver surface toward the transverse colon. We reached a diagnosis of inflammatory pseudotumor (IPT) by a percutaneous liver biopsy. Colonoscopy showed direct invasion of IPT to the colon. His condition improved by the intravenous administration of antibiotics. Hepatic IPT is often misdiagnosed as a malignant tumor. We should consider IPT when we encounter hepatic tumors, and a percutaneous liver biopsy is useful for avoiding unnecessary excessive treatments.


Assuntos
Antibacterianos/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/etiologia , Granuloma de Células Plasmáticas/tratamento farmacológico , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/tratamento farmacológico , Idoso , Neoplasias do Colo/diagnóstico , Neoplasias do Colo/fisiopatologia , Granuloma de Células Plasmáticas/diagnóstico , Granuloma de Células Plasmáticas/fisiopatologia , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/fisiopatologia , Masculino , Metástase Neoplásica/diagnóstico , Metástase Neoplásica/fisiopatologia , Metástase Neoplásica/terapia , Resultado do Tratamento
7.
Intern Med ; 57(21): 3079-3085, 2018 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-29877275

RESUMO

Cronkhite-Canada syndrome (CCS) is a rare non-inherited disease characterized by gastrointestinal polyposis, chronic diarrhea, ectodermal dysplasia, skin hyperpigmentation, hair loss and nail atrophy. Although the efficacy of corticosteroid and immunomodulatory agents has been demonstrated, no standard therapy regimen has been established, and the prognosis of CCS is still poor due to various complications. We here in report a CCS patient complicated with severe sepsis and disseminated intravascular coagulation who was successfully treated by combined modality therapies, including recombinant human soluble thrombomodulin.


Assuntos
Coagulação Intravascular Disseminada/tratamento farmacológico , Polipose Intestinal/tratamento farmacológico , Sepse/complicações , Trombomodulina/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Terapia Combinada , Humanos , Imunomodulação , Masculino , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Proteínas Recombinantes/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA